Company profile: GenMark Diagnostics
1.1 - Company Overview
Company description
- Provider of molecular diagnostics leveraging electrochemical sensor detection to identify up to 72 biomarkers in a single sample. Offers the XT-8 System with FDA 510(k) clearance, the cobas eplex system for automated multiplexed nucleic acid testing via single-use cartridges, and the cobas 4800 System for automated sample prep and real-time PCR supporting sexual health, microbiology, oncology, and genomics.
Products and services
- XT-8 System: FDA 510(k)-cleared platform employing electrochemical sensor technology to detect up to 72 biomarkers per sample
- Cobas® eplex system: Automated in vitro diagnostic device executing multiplexed nucleic acid tests, simultaneously detecting and identifying targets via single-use cartridges
- Cobas® 4800 System: Real-time PCR-based system offering automated sample preparation and amplification/detection, supporting sexual health microbiology, oncology, and genomics testing
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GenMark Diagnostics
PamGene
HQ: The Netherlands
Website
- Description: Provider of kinase activity profiling and diagnostic solutions: IOpener diagnostic blood test measuring protein kinase activity to indicate likelihood of response to ICI therapy; PamChip microarray platform, PamStation instrument, and BioNavigator software; contract research for kinase inhibitor discovery and optimization; and ISO13485 compliant IVD assay services performing IOpener for melanoma and lung cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PamGene company profile →
Syngenta
HQ: Switzerland
Website
- Description: Provider of agricultural technologies and solutions that improve yields, crop resilience, and resource conservation. Offers crop protection from sowing to harvest; seeds and traits for grains, oilseeds, vegetables, fruits, and flowers; TYMIRIUM technology against nematodes and soil-borne pathogens; PERGADO Ultra fungicide for cocoa; and Shoots by Syngenta, a collaborative platform advancing sustainable agriculture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syngenta company profile →
Diagnomics
HQ: United States
Website
- Description: Provider of NGS-based genomics solutions for personalized medicine and next-generation healthcare, offering high-quality R&D and CLIA services including whole genome, exome and RNA sequencing, microarray services, bioinformatics analysis, and clinical/translational research support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnomics company profile →
Medicinal Genomics
HQ: The Netherlands
Website
- Description: Provider of genomics-driven testing and breeding solutions for medical cannabis and hemp, including the PathoSEEK qPCR-based microbial safety testing platform and detection assays for flower, extracts, and infused products; SenSATIVAx DNA purification kits; FemINDICAtor qPCR plant sex testing; and genomic services to identify markers for desirable traits and accelerate breeding programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medicinal Genomics company profile →
Cepheid
HQ: United States
Website
- Description: Provider of accurate, easy-to-use molecular diagnostic systems and tests that automate complex procedures for institutions of any size. Offerings include the GeneXpert System and single-use Xpert cartridges for nucleic acid extraction, amplification, and detection, plus Xpert Xpress PCR tests for Strep A, SARS-CoV-2, CoV-2/Flu/RSV, and Flu A/B.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cepheid company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GenMark Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GenMark Diagnostics
2.2 - Growth funds investing in similar companies to GenMark Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GenMark Diagnostics
4.2 - Public trading comparable groups for GenMark Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →